ProQR Therapeutics (PRQR) Consolidated Net Income (2012 - 2026)

ProQR Therapeutics has reported Consolidated Net Income for 14 years, with the latest figure at -$15.7 million in Q1 2026.

• Quarterly Consolidated Net Income fell 42.54% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.0 million (down 64.86% YoY) and the FY2025 annual result came in at -$50.4 million, down 69.85% from the prior year.
• Consolidated Net Income retreated to -$15.7 million in Q1 2026 per PRQR's latest filing, from -$11.7 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$3.3 million in Q2 2024 and troughed at -$23.4 million in Q3 2022.
• A 5-year average of -$11.4 million and a median of -$11.0 million in 2025 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2023 and 2025: Consolidated Net Income surged 74.74% in 2023, then plunged 312.81% in 2025.
• Over 5 years, Consolidated Net Income stood at -$13.8 million in 2022, then surged by 46.81% to -$7.3 million in 2023, then plunged by 30.05% to -$9.5 million in 2024, then slipped by 22.98% to -$11.7 million in 2025, then tumbled by 33.8% to -$15.7 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$15.7 million, -$11.7 million, and -$12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.